274 related articles for article (PubMed ID: 24532039)
21. Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
Tang L; Zhang H; Peng YZ; Li CG; Jiang HW; Xu M; Mei H; Hu Y
BMC Cancer; 2019 Aug; 19(1):849. PubMed ID: 31462241
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
Radich JP; Kopecky KJ; Appelbaum FR; Kamel-Reid S; Stock W; Malnassy G; Paietta E; Wadleigh M; Larson RA; Emanuel P; Tallman M; Lipton J; Turner AR; Deininger M; Druker BJ
Blood; 2012 Nov; 120(19):3898-905. PubMed ID: 22915637
[TBL] [Abstract][Full Text] [Related]
23. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
Kantarjian H; Cortes J; Kim DW; Dorlhiac-Llacer P; Pasquini R; DiPersio J; Müller MC; Radich JP; Khoury HJ; Khoroshko N; Bradley-Garelik MB; Zhu C; Tallman MS
Blood; 2009 Jun; 113(25):6322-9. PubMed ID: 19369231
[TBL] [Abstract][Full Text] [Related]
24. Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study.
Latagliata R; Ferrero D; Iurlo A; Cavazzini F; Castagnetti F; Abruzzese E; Fava C; Breccia M; Annunziata M; Stagno F; Tiribelli M; Binotto G; Mansueto G; Gozzini A; Russo S; Cavalli L; Montefusco E; Gugliotta G; Cedrone M; Russo Rossi A; Avanzini P; Pregno P; Mauro E; Spadea A; Celesti F; Giglio G; Isidori A; Crugnola M; Calistri E; Sorà F; Storti S; D'Addosio A; Rege-Cambrin G; Luciano L; Alimena G
Drugs Aging; 2013 Aug; 30(8):629-37. PubMed ID: 23681399
[TBL] [Abstract][Full Text] [Related]
25. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
Yeung DT; Osborn MP; White DL; Branford S; Braley J; Herschtal A; Kornhauser M; Issa S; Hiwase DK; Hertzberg M; Schwarer AP; Filshie R; Arthur CK; Kwan YL; Trotman J; Forsyth CJ; Taper J; Ross DM; Beresford J; Tam C; Mills AK; Grigg AP; Hughes TP;
Blood; 2015 Feb; 125(6):915-23. PubMed ID: 25519749
[TBL] [Abstract][Full Text] [Related]
26. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
Wang J; Shen ZX; Saglio G; Jin J; Huang H; Hu Y; Du X; Li J; Meng F; Zhu H; Hu J; Wang J; Hou M; Hertle S; Menssen HD; Ortmann CE; Tribouley C; Yuan Y; Baccarani M; Huang X
Blood; 2015 Apr; 125(18):2771-8. PubMed ID: 25766724
[TBL] [Abstract][Full Text] [Related]
27. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Wei G; Rafiyath S; Liu D
J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
[TBL] [Abstract][Full Text] [Related]
28. Extending the reach of nilotinib in chronic myeloid leukemia.
Mauro MJ
Haematologica; 2014 Jul; 99(7):1123-4. PubMed ID: 24986871
[No Abstract] [Full Text] [Related]
29. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up.
Gallipoli P; Stobo J; Heaney N; Nicolini FE; Clark R; Wilson G; Tighe J; McLintock L; Hughes T; Michor F; Paul J; Drummond M; Holyoake TL
Br J Haematol; 2013 Dec; 163(5):674-6. PubMed ID: 24032404
[No Abstract] [Full Text] [Related]
30. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
Larson RA; Hochhaus A; Hughes TP; Clark RE; Etienne G; Kim DW; Flinn IW; Kurokawa M; Moiraghi B; Yu R; Blakesley RE; Gallagher NJ; Saglio G; Kantarjian HM
Leukemia; 2012 Oct; 26(10):2197-203. PubMed ID: 22699418
[TBL] [Abstract][Full Text] [Related]
31. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Kantarjian H; Giles F; Wunderle L; Bhalla K; O'Brien S; Wassmann B; Tanaka C; Manley P; Rae P; Mietlowski W; Bochinski K; Hochhaus A; Griffin JD; Hoelzer D; Albitar M; Dugan M; Cortes J; Alland L; Ottmann OG
N Engl J Med; 2006 Jun; 354(24):2542-51. PubMed ID: 16775235
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
[TBL] [Abstract][Full Text] [Related]
33. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
[TBL] [Abstract][Full Text] [Related]
34. Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
Giles FJ; Yin OQ; Sallas WM; le Coutre PD; Woodman RC; Ottmann OG; Baccarani M; Kantarjian HM
Eur J Clin Pharmacol; 2013 Apr; 69(4):813-23. PubMed ID: 23052406
[TBL] [Abstract][Full Text] [Related]
35. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.
Shah NP; Kantarjian HM; Kim DW; Réa D; Dorlhiac-Llacer PE; Milone JH; Vela-Ojeda J; Silver RT; Khoury HJ; Charbonnier A; Khoroshko N; Paquette RL; Deininger M; Collins RH; Otero I; Hughes T; Bleickardt E; Strauss L; Francis S; Hochhaus A
J Clin Oncol; 2008 Jul; 26(19):3204-12. PubMed ID: 18541900
[TBL] [Abstract][Full Text] [Related]
36. The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose.
Breccia M; Alimena G
Expert Opin Pharmacother; 2011 Sep; 12(13):2075-87. PubMed ID: 21721847
[TBL] [Abstract][Full Text] [Related]
37. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
38. High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis.
Gafter-Gvili A; Leader A; Gurion R; Vidal L; Ram R; Shacham-Abulafia A; Ben-Bassat I; Lishner M; Shpilberg O; Raanani P
Am J Hematol; 2011 Aug; 86(8):657-62. PubMed ID: 21761431
[TBL] [Abstract][Full Text] [Related]
39. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
Kantarjian H; Pasquini R; Lévy V; Jootar S; Holowiecki J; Hamerschlak N; Hughes T; Bleickardt E; Dejardin D; Cortes J; Shah NP
Cancer; 2009 Sep; 115(18):4136-47. PubMed ID: 19536906
[TBL] [Abstract][Full Text] [Related]
40. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.
Khoury HJ; Cortes JE; Kantarjian HM; Gambacorti-Passerini C; Baccarani M; Kim DW; Zaritskey A; Countouriotis A; Besson N; Leip E; Kelly V; Brümmendorf TH
Blood; 2012 Apr; 119(15):3403-12. PubMed ID: 22371878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]